SCHEMBL1463744

SCHEMBL1463744

NC(=O)c1nc(-c2ccc(Cl)cc2)ccc1N

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP2K3 P46734 3/20 0.71
IKBKB O14920 3/20 0.53
MAP4K4 O95819 4/20 0.51
CASP1 P29466 1/20 0.46
KMO O15229 1/20 0.44
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK14 Q16539 1/20 0.43
ATR Q13535 1/20 0.43
PARP1 P09874 1/20 0.43
MAP3K14 Q99558 1/20 0.40
CTRC Q99895 1/20 0.40
NR4A2 P43354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1792072 0.83 MAP2K3 (0.71) MAP2K3IKBKBNPC1RAB9ASMN1; SMN2
SCHEMBL1463746 0.74 MAPT (0.47) MAP4K4KMOMAPTNPC1NFKB1
SCHEMBL668419 0.74 MAP2K3 (0.53) MAP2K3IKBKBSMN1; SMN2
SCHEMBL26684503 0.72 MAP2K3 (0.68) MAP2K3IKBKBNPC1RAB9AMAPK14
SCHEMBL16506308 0.72 MAP2K3 (0.68) MAP2K3IKBKBMAPTNPC1RAB9A
SCHEMBL4514671 0.72 MAP2K3 (0.68) MAP2K3MAP4K4KMOMAPTATR
SCHEMBL11908303 0.71 MAP2K3 (0.73) MAP2K3IKBKBMAPTNPC1NFKB1
SCHEMBL11681871 0.71 PARP1 (0.53) IKBKBMAP4K4CASP1KMOMAPT
SCHEMBL2468156 0.71 CTRC (0.51) CASP1KMOMAPTNPC1RAB9A
SCHEMBL11908374 0.70 MAP2K3 (0.77) MAP2K3IKBKBCASP1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071162-A1 TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-24 US disclosed
US-7863279-B2 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-01-04 US disclosed
US-20100041670-A1 TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-02-18 US disclosed
EP-2146992-A1 TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-01-27 EP disclosed
WO-2008145843-A1 TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071162-A1 TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF FLT3, GLS, GLP1R MAP2K3 2440/4885IKBKB 2267/4885MAP4K4 825/4885
US-20100041670-A1 TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF FLT3, GLP1R, GLS MAP2K3 2219/4885IKBKB 2484/4885MAP4K4 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.